Chen Schor, Adicet CEO

Adicet un­veils ear­ly re­spons­es for off-the-shelf drug lever­ag­ing rare T cells. Will dura­bil­i­ty hold up?

On the hunt for the next gen­er­a­tion of “off-the-shelf” cell ther­a­pies, biotech play­ers like Adicet Bio have looked to lever­age some of the less-ob­vi­ous mem­bers of the im­mune sys­tem as po­tent can­cer fight­ers. In Adicet’s case, scarce gam­ma delta T cells are on the menu, and an ear­ly cut of da­ta is show­ing some promise.

Adicet’s AD-001, an off-the-shelf cell ther­a­py de­vel­oped by en­gi­neer­ing a CD20-tar­get­ing chimeric anti­gen re­cep­tor (CAR) on­to a donor’s gam­ma delta T cells, post­ed two com­plete re­spons­es across four pa­tients in an ear­ly Phase I study test­ing the drug in pa­tients with heav­i­ly pre­treat­ed B cell non-Hodgkin’s lym­phoma, the biotech said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.